-
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
•
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA) to initiate a clinical study for its FT-003, a recombinant adeno-associated virus (rAAV) gene therapy for diabetic retinopathy (DR). This follows previous approvals for studies in neovascular age-related macular degeneration (nAMD) and diabetic macular edema…
-
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
•
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II study assessing its recombinant adeno-associated virus (rAAV) gene therapy, FT-003, in patients with diabetic macular edema (DME). This follows previous clearance for a Phase II…
-
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
•
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II clinical study for its investigational drug FT-003. This recombinant adeno-associated virus (rAAV) gene therapy is designed for the treatment of neovascular age-related macular…
-
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
•
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase II clinical study for its investigational gene therapy, FT-002. This recombinant adeno-associated virus (rAAV) gene therapy candidate marks a significant milestone as the…
-
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
•
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical study for its in-house developed gene therapy FT-002. This marks a significant milestone in the development of treatments for X-linked retinitis pigmentosa (XLRP), a genetic disorder affecting vision. FT-002: First-in-Class Gene TherapyFT-002 is a recombinant…
-
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
•
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round, bringing total investments in the firm to $195 million. The round follows a $35 million Series A led by OrbiMed and Creacion Ventures. Investors in the latest round include Boyu Capital, Sequoia China, OrbiMed, and…
